PCSK9 shots for calcified aortic valve narrowing
Part of Heart & circulation clinical trials.
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old and have aortic valve narrowing in one of these ranges: mild/moderate, or severe but without symptoms and a negative exercise test
- You must already be on a stable statin dose (atorvastatin or rosuvastatin) for at least 4 weeks
- Your LDL (“bad cholesterol”) is still high enough (or in the allowed range) plus you have at least 1 major or 3 minor heart-risk factors
- You have not taken PCSK9 inhibitor treatment before
- You can stay on the study medicines for 24 months and are not allergic to PCSK9 inhibitors or statins
- You do not have major exclusions like serious liver/kidney problems, recent steroid/cyclosporine use, uncontrolled arrhythmias, planned valve surgery, or a life expectancy under 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a newer cholesterol-lowering medicine can slow down the narrowing of the heart's main valve in people with aortic stenosis. If you qualify, you may be able to take this medicine to potentially delay the need for surgery.
This study develops and tests a new way to diagnose severe aortic stenosis (narrowing of the aortic valve) by measuring calcium buildup on the valve using heart ultrasound. If you're already getting both an ultrasound and a CT scan of your heart, this study compares how well the ultrasound method can identify severe stenosis.
This trial tests a drug called a PCSK9 inhibitor, which lowers cholesterol. It may slow down the buildup of calcium in the aortic valve, which can narrow the valve and make it harder for blood to flow. The drug is given as an injection, and you would receive it for 24 months.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This trial tests whether adding a PCSK9 inhibitor to standard statin therapy can help people with narrowing in brain arteries that hasn't caused symptoms yet. The goal is to see if this combination lowers plaque and prevents future strokes.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.